Log in

NASDAQ:DCPHDeciphera Pharmaceuticals Stock Price, Forecast & News

$48.91
+1.01 (+2.11 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$47.54
Now: $48.91
$49.26
50-Day Range
$46.07
MA: $53.89
$64.22
52-Week Range
$19.88
Now: $48.91
$71.11
Volume366,294 shs
Average Volume380,304 shs
Market Capitalization$2.76 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.97
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Read More
Deciphera Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DCPH
CUSIPN/A
Phone781-209-6400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$25 million
Book Value$10.99 per share

Profitability

Net Income$-192,260,000.00

Miscellaneous

Employees112
Market Cap$2.76 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$48.91
+1.01 (+2.11 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions

How has Deciphera Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DCPH shares have increased by 10.1% and is now trading at $48.91.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Deciphera Pharmaceuticals?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Deciphera Pharmaceuticals
.

When is Deciphera Pharmaceuticals' next earnings date?

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Deciphera Pharmaceuticals
.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) posted its earnings results on Tuesday, August, 4th. The company reported ($1.20) EPS for the quarter, topping the consensus estimate of ($1.34) by $0.14.
View Deciphera Pharmaceuticals' earnings history
.

What price target have analysts set for DCPH?

15 brokers have issued 12-month price objectives for Deciphera Pharmaceuticals' stock. Their forecasts range from $49.00 to $91.00. On average, they expect Deciphera Pharmaceuticals' share price to reach $70.00 in the next year. This suggests a possible upside of 43.1% from the stock's current price.
View analysts' price targets for Deciphera Pharmaceuticals
.

Has Deciphera Pharmaceuticals been receiving favorable news coverage?

News coverage about DCPH stock has trended very positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Deciphera Pharmaceuticals earned a news impact score of 4.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Deciphera Pharmaceuticals
.

Who are some of Deciphera Pharmaceuticals' key competitors?

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include Ionis Pharmaceuticals (IONS), Allena Pharmaceuticals (ALNA), Viking Therapeutics (VKTX), GW Pharmaceuticals PLC- (GWPH), Immunomedics (IMMU), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), AbbVie (ABBV), Bausch Health Companies (BHC) and Cytokinetics (CYTK).

Who are Deciphera Pharmaceuticals' key executives?

Deciphera Pharmaceuticals' management team includes the following people:
  • Dr. Daniel L. Flynn, Exec. VP, Chief Scientific Officer & Founder (Age 64)
  • Mr. Christopher J. Morl, Chief Bus. Officer (Age 60)
  • Countess Steven L. Hoerter, Pres, CEO & Director (Age 48)
  • Mr. Thomas Patrick Kelly J.D., Exec. VP, CFO & Treasurer (Age 48)
  • Dr. Stephen B. Ruddy Ph.D., Chief Technical Officer (Age 55)

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include TimesSquare Capital Management LLC (0.99%), Candriam Luxembourg S.C.A. (0.45%), Emerald Advisers LLC (0.36%), Kornitzer Capital Management Inc. KS (0.35%), Emerald Mutual Fund Advisers Trust (0.34%) and Swiss National Bank (0.14%). Company insiders that own Deciphera Pharmaceuticals stock include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly.
View institutional ownership trends for Deciphera Pharmaceuticals
.

Which institutional investors are selling Deciphera Pharmaceuticals stock?

DCPH stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., TimesSquare Capital Management LLC, Strs Ohio, SG Americas Securities LLC, and Kornitzer Capital Management Inc. KS. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen, and Thomas Patrick Kelly.
View insider buying and selling activity for Deciphera Pharmaceuticals
.

Which institutional investors are buying Deciphera Pharmaceuticals stock?

DCPH stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Swiss National Bank, Mackay Shields LLC, Rafferty Asset Management LLC, New York State Common Retirement Fund, and WINTON GROUP Ltd.
View insider buying and selling activity for Deciphera Pharmaceuticals
.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $48.91.

How big of a company is Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals has a market capitalization of $2.76 billion and generates $25 million in revenue each year. The company earns $-192,260,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.

What is Deciphera Pharmaceuticals' official website?

The official website for Deciphera Pharmaceuticals is www.deciphera.com.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.